Use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity
Pharmaceutical compositions in which isolated cannabinoid receptor modulators are optionally combined with terpene blends in a pharmaceutically acceptable carrier. Methods for treating or preventing a disease, disorder, dysfunction or condition caused by exposure to an organophosphate or carbamate acetylcholinesterase inhibitor with the inventive compositions are also disclosed.
1. A method for treating symptoms caused by exposure to sarin or aldicarb comprising:
(i) administering a composition comprising tetrahydrocannabinol (THC) and cannabidiol (CBD) to a subject exposed to sarin or aldicarb, wherein the THC and CBD are in a therapeutically-effective amount to treat the symptoms, wherein the administration of the THC/CBD composition is oral, nasal, buccal, sublingual, or parenteral; and
(ii) optionally administering a composition of linalool and beta-caryophyllene; wherein the administration of the linalool is via a gas mask.
2. The method of claim 1 wherein the ratio of THC:CBD is about 1:10 to about 1:40.
3. The method of claim 1 wherein the amount of THC is about 0.0001 mg to about 10 mg and the amount of CBD is about 3 mg to about 400 mg.
4. The method of claim 1 wherein step (ii) is required and linalool and beta-caryophyllene are in a ratio of from 6:0.25 to 1:3.
5. The method of claim 1 wherein step (ii) is required and linalool and beta-caryophyllene are in a ratio of 3:1.
6. The method of claim 1 wherein step (ii) is required and linalool and beta-caryophyllene are in a ratio of 3:2.
7. The method of claim 1 further comprising administering a non-cannabinoid active ingredient estazolam.
8. The method of claim 1 , further comprising administering flurazepam.
9. The method of claim 1 wherein the THC is (6aR,10aR)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol.
10. The method of claim 1 wherein the administration of the THC/CBD composition is parenteral.
11. The method of claim 10 wherein the parenteral administration of the THC/CBD composition is an intramuscular injection.
12. The method of claim 10 wherein the parenteral administration of the THC/CBD composition is an intravenous injection.
13. The method of claim 1 wherein the THC/CBD composition is administered orally.
14. The method of claim 1 wherein the THC/CBD composition is administered sublingually.
15. The method of claim 1 wherein the THC/CBD composition is administered buccally.
16. The method of claim 1 wherein the THC/CBD composition is administered nasally.
17. The method of claim 1 wherein step (ii) is required and the administration of the linalool and beta-caryophyllene is via a gas mask.
18. The method of claim 1 , wherein step (ii) is required.